Short Interest in Certara, Inc. (NASDAQ:CERT) Drops By 15.7%

Certara, Inc. (NASDAQ:CERT) saw a large decline in short interest in June. As of June 15th, there was short interest totalling 4,400,000 shares, a decline of 15.7% from the May 31st total of 5,220,000 shares. Based on an average daily volume of 576,300 shares, the short-interest ratio is presently 7.6 days. Approximately 4.0% of the company’s stock are sold short.

Insider Activity at Certara

In other Certara news, insider Patrick F. Smith sold 14,427 shares of Certara stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at $844,033.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Pineridge Advisors LLC purchased a new stake in Certara in the 4th quarter worth approximately $28,000. Global Retirement Partners LLC boosted its position in shares of Certara by 5,306.3% in the first quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock worth $31,000 after purchasing an additional 1,698 shares during the period. YHB Investment Advisors Inc. purchased a new stake in shares of Certara in the first quarter worth $47,000. Pacer Advisors Inc. raised its position in shares of Certara by 1,704.0% during the 4th quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock valued at $224,000 after purchasing an additional 12,047 shares during the period. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Certara during the 1st quarter valued at $245,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

CERT stock traded down $0.21 during midday trading on Monday, reaching $13.64. 665,945 shares of the company’s stock traded hands, compared to its average volume of 567,172. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara has a 52-week low of $11.81 and a 52-week high of $19.87. The stock has a market cap of $2.19 billion, a P/E ratio of -34.97, a PEG ratio of 4.65 and a beta of 1.53. The stock’s 50-day moving average is $15.98 and its 200 day moving average is $16.86.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $96.65 million during the quarter, compared to analysts’ expectations of $94.48 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. As a group, analysts anticipate that Certara will post 0.29 EPS for the current year.

Analysts Set New Price Targets

CERT has been the subject of several recent analyst reports. KeyCorp upgraded Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 price target for the company in a research note on Wednesday, April 10th. Barclays dropped their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, JMP Securities initiated coverage on shares of Certara in a report on Thursday, April 4th. They set a “market perform” rating for the company. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Certara currently has an average rating of “Hold” and an average target price of $19.81.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.